Plasma biomarkers for afatinib monotherapy in EGFR-mutated non-small cell lung cancer: Novel insights from companion genomics analysis of the EXTRA study.

doi:10.1016/j.ctarc.2025.100952

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Plasma biomarkers for afatinib monotherapy in EGFR-mutated non-small cell lung cancer: Novel insights from companion genomics analysis of the EXTRA study.

Cancer treatment and research communications - 1 Jan 2025

Makiguchi Tomonori, Tanaka Hisashi, Morikawa Kei, Hirata Aya, Itani Hidetoshi, Tanzawa Shigeru, Watanabe Kageaki, Yasuda Hiroyuki, Horiuchi Kazuya, Nakagawa Hideyuki, Seki Yoshitaka, Nakahara Yoshiro, Hayashi Kentaro, Takahashi Nobumasa, Endo Takeo, Bessho Akihiro, Okano Tetsuya, Takeyama Kiyoshi, Kawase Akikazu, Endo Makoto, Maekura Toshiya, Nemoto Kenji, Takigawa Nagio, Kishi Kazuma, Soejima Kenzo, Okuma Yusuke, Togashi Akira, Matsutani Noriyuki, Shinchi Hiroki, Ueda Koji, Seki Nobuhiko

Abstract excerpt

OBJECTIVES: Plasma-based testing with circulating cell-free DNA (cfDNA) is an active area of biomarker exploratory studies in patients with non-small cell lung cancer (NSCLC) harboring EGFR mutations. The Exosome-focused Translational Research for Afatinib study prospectively explored novel plasma biomarkers for afatinib monotherapy in patients with NSCLC harboring EGFR mutations using genomics, proteomics,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Afatinib

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Biomarkers, Tumor

Share to Carcinoma, Non-Small-Cell Lung

Share to Cell-Free Nucleic Acids

Share to ErbB Receptors

Share to Genomics

Share to High-Throughput Nucleotide Sequencing

Share to Protein Kinase Inhibitors

Source

Open in PubMed

Identifiers

PMID: 40466414
DOI: 10.1016/j.ctarc.2025.100952

Genes

EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Plasma biomarkers for afatinib monotherapy in EGFR-mutated non-small cell lung cancer: Novel insights from companion genomics analysis of the EXTRA study.PMID 40466414Read ↗

Biomarker subset analysis of a phase IIIb, open-label study of afatinib in EGFR tyrosine kinase inhibitor-naive patients with EGFRm+ non-small-cell lung cancer.Semantic proximity Read ↗

Plasma Cell-Free DNA Genotyping: From an Emerging Concept to a Standard-of-Care Tool in Metastatic Non-Small Cell Lung Cancer.Semantic proximity Read ↗

Monitoring of somatic mutations in circulating cell-free DNA by digital PCR and next-generation sequencing during afatinib treatment in patients with lung adenocarcinoma positive for EGFR activating mutations.Semantic proximity Read ↗

Phase II open-label multicenter study to assess the antitumor activity of afatinib in lung cancer patients with activating epidermal growth factor receptor mutation from circulating tumor DNA: Liquid-Lung-A.Semantic proximity Read ↗

Determination of Somatic Mutations and Tumor Mutation Burden in Plasma by CAPP-Seq during Afatinib Treatment in NSCLC Patients Resistance to Osimertinib.Semantic proximity Read ↗

Clinical utility of liquid biopsy for EGFR driver, T790M mutation and EGFR amplification in plasma in patients with acquired resistance to afatinib.Semantic proximity Read ↗

Clinical utility of liquid biopsy for EGFR driver, T790M mutation and EGFR amplification in plasma in patients with acquired resistance to afatinibSemantic proximity Read ↗

A Prospective Evaluation of Circulating Tumor Cells and Cell-Free DNA in EGFR-Mutant Non-Small Cell Lung Cancer Patients Treated with Erlotinib on a Phase II Trial.Semantic proximity Read ↗

Variations in EGFR ctDNA Correlates to the Clinical Efficacy of Afatinib in Non Small Cell Lung Cancer with Acquired Resistance.Semantic proximity Read ↗

Detection of Plasma EGFR Mutations in NSCLC Patients with a Validated ddPCR Lung cfDNA AssaySemantic proximity Read ↗

EGFR mutation analysis on circulating free DNA in NSCLC: a single-center experience.Semantic proximity Read ↗

Mutational monitoring of EGFR T790M in cfDNA for clinical outcome prediction in EGFR-mutant lung adenocarcinomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.